Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Futuximab + Modotuximab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Futuximab | 992 DS|992-DS|992DS | EGFR Antibody 60 | Futuximab (992 DS) is a recombinant human-mouse chimeric monoclonal antibody that targets a specific EGFR epitope (PMID: 29564747). | |
Modotuximab | 1024 DS|1024-DS|Zatuximab | EGFR Antibody 60 | Modotuximab (1024 DS) is a recombinant human-mouse chimeric monoclonal antibody that targets a specific EGFR epitope (PMID: 29564747). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05223673 | Phase III | Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR) | Terminated | USA | HUN | FIN | DNK | BEL | 1 |